Wall Street brokerages predict that Dynavax Technologies Co. (NASDAQ:DVAX) will announce sales of $3.55 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Dynavax Technologies’ earnings. The lowest sales estimate is $3.00 million and the highest is $4.10 million. Dynavax Technologies reported sales of $50,000.00 in the same quarter last year, which would suggest a positive year-over-year growth rate of 7,000%. The company is scheduled to announce its next quarterly earnings report on Friday, November 2nd.

According to Zacks, analysts expect that Dynavax Technologies will report full-year sales of $11.62 million for the current fiscal year, with estimates ranging from $7.96 million to $15.27 million. For the next financial year, analysts expect that the company will post sales of $93.41 million, with estimates ranging from $88.23 million to $98.58 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that cover Dynavax Technologies.

Dynavax Technologies (NASDAQ:DVAX) last posted its earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.63) EPS for the quarter, missing the consensus estimate of ($0.62) by ($0.01). The firm had revenue of $1.25 million during the quarter, compared to the consensus estimate of $1.88 million. Dynavax Technologies had a negative net margin of 8,570.06% and a negative return on equity of 72.31%. Dynavax Technologies’s revenue for the quarter was up 1094.3% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.41) earnings per share.

A number of equities analysts have recently issued reports on the company. Cantor Fitzgerald restated a “buy” rating and set a $30.00 price objective on shares of Dynavax Technologies in a research report on Monday, August 6th. ValuEngine downgraded Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Monday, July 30th. BidaskClub downgraded Dynavax Technologies from a “hold” rating to a “sell” rating in a research report on Friday, June 8th. Finally, Zacks Investment Research raised Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Thursday, August 9th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. Dynavax Technologies has an average rating of “Hold” and an average target price of $27.50.

Institutional investors have recently made changes to their positions in the business. Bank of Montreal Can grew its stake in Dynavax Technologies by 365.4% in the second quarter. Bank of Montreal Can now owns 13,938 shares of the biopharmaceutical company’s stock valued at $213,000 after acquiring an additional 10,943 shares during the period. Chicago Capital LLC grew its stake in Dynavax Technologies by 48.3% in the second quarter. Chicago Capital LLC now owns 1,294,104 shares of the biopharmaceutical company’s stock valued at $19,735,000 after acquiring an additional 421,446 shares during the period. Creative Planning grew its stake in Dynavax Technologies by 2.6% in the second quarter. Creative Planning now owns 235,105 shares of the biopharmaceutical company’s stock valued at $3,585,000 after acquiring an additional 5,857 shares during the period. Xact Kapitalforvaltning AB acquired a new stake in Dynavax Technologies in the first quarter valued at approximately $200,000. Finally, Tiverton Asset Management LLC acquired a new stake in Dynavax Technologies in the second quarter valued at approximately $184,000. 82.02% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies stock traded up $0.50 during trading hours on Friday, hitting $12.90. The stock had a trading volume of 17,771 shares, compared to its average volume of 831,618. The company has a current ratio of 8.87, a quick ratio of 8.67 and a debt-to-equity ratio of 0.76. The company has a market capitalization of $751.39 million, a PE ratio of -7.38 and a beta of 0.24. Dynavax Technologies has a one year low of $11.35 and a one year high of $24.45.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

See Also: What is the S&P 500 Index?

Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.